The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
oleh: Sambit Tripathy
| Format: | Article |
|---|---|
| Diterbitkan: | Wolters Kluwer Medknow Publications 2021-01-01 |
Deskripsi
No description available for this item.